Cite
HARVARD Citation
Kümmel, S. et al. (2017). Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). European journal of cancer. pp. 1-8. [Online].